Beijing Chieftain Control Engineering Technology (300430.SZ) has two main business sectors: CSI SWS Health Care Index and intelligent manufacturing sector, as well as a rehabilitation medical device sector.

On July 15th, GeLongHui reported that Beijing Chieftain Control Engineering Technology(300430.SZ) stated on the investor interaction platform that the company's business is mainly divided into the medical and biopharmaceutical intelligent manufacturing sector and the rehabilitation medical equipment sector. The medical and biopharmaceutical intelligent manufacturing sector mainly provides personalized overall solutions for pharmaceutical and biopharmaceutical manufacturing enterprises. The rehabilitation medical equipment sector mainly provides rehabilitation products and services for medical institutions, retirement institutions, sports training institutions and other institutions represented by comprehensive hospital rehabilitation departments.

Gelonghui FinanceJul 15 04:07 ET

Innovative Phar announced its annual performance, with a net profit attributable to shareholders of HK$103 million, turning losses into gains year-on-year.

In the fiscal year ending March 31, 2024, innovative phar (00399) announced its annual results, with a revenue of HKD 6.59 million, a decrease of 18.35% year-on-year; the net profit attributable to shareholders was HKD 103 million, compared to a loss of HKD 2.46 billion in the same period last year; basic earnings per share was HKD 0.0677. The announcement stated that the main reason for the turnaround was due to the revenue from the revised convertible bonds of HKD 330 million obtained in this fiscal year.

新浪港股Jun 30 21:36 ET

Innovative Phar (00399) announced its annual performance, with a shareholder's share of HKD 103 million in net profit, turning losses into gains year-on-year.

Innovative phar (00399) released its annual performance report for the year ending March 31, 2024, with the group achieving revenue...

Zhitong FinanceJun 28 10:50 ET

Innovative phar renews cooperation agreement with Tsinghua University.

Innovative phar (00399) released a statement stating that the ongoing development project (R & D process) refers to the ongoing development project of the product. Fushi Biotech Co., Ltd. (Fushi) is a subsidiary of EOS Ventures and became a subsidiary of the company after completing the acquisition on July 28, 2014. Fushi and Peking Tsinghua University (Tsinghua University) signed multiple agreements in 1998 related to the research and development of products (Tsinghua University Cooperative Agreement). According to the agreement, it will expire in October 2018 and was extended until October 2023 through a supplement agreement signed on November 12, 2018.

新浪港股Jun 25 19:40 ET

Innovative phar (00399) renews cooperation agreement with Tsinghua University on healthcare and biology.

Linghang Pharmaceutical Biotechnology (00399) announced that the ongoing research and development project refers to the product being developed. Fushi Biotechnology Co., Ltd. (Fushi) is a subsidiary of Jinsen Co., Ltd. and became the company's subsidiary after completing the acquisition on July 28, 2014. Fushi and Tsinghua University (Tsinghua University) signed multiple agreements in 1998 regarding the development of products (Tsinghua University Cooperation Agreement). According to the agreement, it will expire in October 2018 and was extended by a supplementary agreement signed on November 12, 2018.

Zhitong FinanceJun 25 10:53 ET

Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET